Advanced-glycation end-products axis:A contributor to the risk of severe illness from COVID-19 in diabetes patients  

作　　者：Armando Rojas Cristian Lindner Ileana Gonzàlez Miguel Angel Morales 

机构地区：[1]Biomedical Research Labs,Medicine Faculty,Catholic University of Maule,Talca 3460000,Chile [2]Medicine Faculty,Catholic University of Maule,Talca 3460000,Chile [3]Molecular and Clinical Pharmacology Program,Institute of Biomedical Sciences,University of Chile,Santiago 8320000,Chile

出　　处：《World Journal of Diabetes》2021年第5期590-602,共13页世界糖尿病杂志（英文版）（电子版）

摘　　要：Compelling pieces of evidence derived from both clinical and experimental research has demonstrated the crucial role of the receptor for advanced-glycation end-products(RAGE)in orchestrating a plethora of proinflammatory cellular responses leading to many of the complications and end-organ damages reported in patients with diabetes mellitus(DM).During the coronavirus disease 2019(COVID-19)pandemic,many clinical reports have pointed out that DM increases the risk of COVID-19 complications,hospitalization requirements,as well as the overall severe acute respiratory syndrome coronavirus 2 case-fatality rate.In the present review,we intend to focus on how the basal activation state of the RAGE axis in common preexisting conditions in DM patients such as endothelial dysfunction and hyperglycemia-related prothrombotic phenotype,as well as the contribution of RAGE signaling in lung inflammation,may then lead to the increased mortality risk of COVID-19 in these patients.Additionally,the crosstalk between the RAGE axis with either another severe acute respiratory syndrome coronavirus 2 receptor molecule different of angiotensin-converting enzyme 2 or the renin-angiotensin system imbalance produced by viral infection,as well as the role of this multi-ligand receptor on the obesity-associated lowgrade inflammation in the higher risk for severe illness reported in diabetes patients with COVID-19,are also discussed.

关 键 词：COVID-19 Diabetes mellitus Advanced glycation ALARMINS Advancedglycation end-products axis Inflammation 

分 类 号：R587.2[医药卫生—内分泌] R563.1[医药卫生—内科学]